Stockreport

vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes

vTv Therapeutics Inc. - Class A  (VTVT) 
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vtvtherapeutics.com
PDF TTP399, a novel glucokinase activator shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia HIGH POINT, N [Read more]